{\rtf1\ansi\ansicpg1252\uc1\deff0\deflang1033 {\colortbl\red0\green0\blue0;\red128\green128\blue128;\red255\green255\blue255;\red207\green240\blue252;}{\fonttbl{\f2\fswiss Arial;}{\f1\fmodern Courier New;}{\f3\fdecor Symbol;}{\f0\froman Times New Roman;}{\f4\fnil Wingdings;}} {\info{\subject EDGAR Online Pro}{\version3}{\*\company EDGAR Online, a division of Donnelley Financial Solutions}{\author EDGAR Online HTML to RTF Converter. Version 3.0}{\*\category \0001564590-21-006201.html.ecq}{\doccomm Source: EDGAR Online, a division of Donnelley Financial Solutions \'a9 Copyright 2021. All rights reserved.}{\title ACORDA THERAPEUTICS INC (Form: 8-K, Received: 02/17/2021 07:50:39)}} \paperh15840\paperw12240\margl360\margr360\margt360\margb360\headery0\footery0\sprstsp\sprsbsp\sprsspbf\sprslnsp\widowctrl\viewscale100 {\*\bkmkstart BKMK_1}{\*\bkmkend BKMK_1}{\*\bkmkstart BKMK_2}{\*\bkmkend BKMK_2}{\*\bkmkstart BKMK_3}{\*\bkmkend BKMK_3}{\*\bkmkstart BKMK_4}{\*\bkmkend BKMK_4}\pard {\fs18 \u160?}\par \pard \brdrt\brdrdb\brdrw40\brdrcf0 \sb58 {\fs18 \u160?}\par \pard \qc {\fs32\b UNITED STATES}\par \pard \qc {\fs32\b SECURITIES AND EXCHANGE COMMISSION}\par \pard \qc {\fs22\b WASHINGTON, D.C. 20549}\par \pard \brdrb\brdrs\brdrw18\brdrcf0\qc \li4608\ri4608\sb162 {\fs11 \u160?}\par \pard \qc \sb162 {\fs32\b FORM 8-K}\par \pard \brdrb\brdrs\brdrw18\brdrcf0\qc \li4608\ri4608\sb162 {\fs11 \u160?}\par \pard \qc \sb162 {\fs22\b CURRENT REPORT}\par \pard \qc \sb162 {\fs22\b Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934}\par \pard \qc \sb162 {\fs18\b Date of Report (Date of earliest event reported): February 10, 2021}\par \pard \brdrb\brdrs\brdrw18\brdrcf0\qc \li4608\ri4608\sb162 {\fs11 \u160?}{\*\bkmkstart BKMK_5}{\*\bkmkend BKMK_5}\par \pard \qc \sb216 {\fs40\b Acorda Therapeutics, Inc.}\par \pard \qc {\fs14\b (Exact name of Registrant as Specified in Its Charter)}\par \pard \brdrb\brdrs\brdrw18\brdrcf0\qc \li4608\ri4608\sb162 {\fs11 \u160?}\par \pard \sb36 {\fs16 \u160?}\par {\trowd\trleft0\clvertalb\cellx3795 \clvertalb\cellx7590 \clvertalb\cellx11385 \clvertalc\cellx11520 \pard \intbl\qc \ri16 {\fs18\b Delaware}\cell \pard \intbl\qc \ri16 {\fs18\b 001-31938}\cell \pard \intbl\qc \ri16 {\fs18\b 13-3831168}\cell \pard \intbl\sl-1\vertalc \cell \row} {\trowd\trleft0\clvertalb\cellx3795 \clvertalb\cellx7590 \clvertalb\cellx11385 \cellx11520 \pard \intbl\qc \ri16 {\fs14\b (State or Other Jurisdiction}\par \pard \intbl\qc \ri16 {\fs14\b of Incorporation)}\cell \pard \intbl\qc \ri16 {\fs14\b (Commission File Number)}\cell \pard \intbl\qc \ri16 {\fs14\b (IRS Employer}\par \pard \intbl\qc \ri16 {\fs14\b Identification No.)}\cell \pard\intbl\cell \row \pard \intbl \ri16 {\fs18 \u160?}\cell \pard \intbl \ri16 {\fs18 \u160?}\cell \pard \intbl \ri16 {\fs18 \u160?}\cell \pard\intbl\cell \row \pard \intbl\qc \ri16 {\fs18\b 420 Saw Mill River Road,}\par \pard \intbl\qc \ri16 {\fs18\b Ardsley, NY}\cell \pard \intbl \li129 {\fs8 \u160?}\cell \pard \intbl\qc \ri16 {\fs18\b 10502}\cell \pard\intbl\cell \row \pard \intbl\qc \ri16 {\fs14\b (Address of Principal Executive Offices)}\cell \pard \intbl \li129 {\fs8 \u160?}\cell \pard \intbl\qc \ri16 {\fs14\b (Zip Code)}\cell \pard\intbl\cell \row} \pard \qc \sb162 {\fs18\b Registrant\u8217?s Telephone Number, Including Area Code: (914) 347-4300}\par \pard \qc \sb162 {\fs18\b Not Applicable}\par \pard \qc {\fs14\b (Former Name or Former Address, if Changed Since Last Report)}\par \pard \brdrb\brdrs\brdrw18\brdrcf0\qc \li4608\ri4608\sb162 {\fs11 \u160?}\par \pard \sb162 {\fs18 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):}\par \pard {\fs16 \u160?}\par {\trowd\trleft0\cellx480 \cellx11520 \pard \intbl \ri16 {\fs18 \u9744?}\cell \pard \intbl \ri16 {\fs18 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)}\cell \row \pard \intbl \ri16 {\fs18 \u9744?}\cell \pard \intbl \ri16 {\fs18 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)}\cell \row \pard \intbl \ri16 {\fs18 \u9744?}\cell \pard \intbl \ri16 {\fs18 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))}\cell \row \pard \intbl \ri16 {\fs18 \u9744?}\cell \pard \intbl \ri16 {\fs18 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))}\cell \row} {\*\bkmkstart BKMK_6}{\*\bkmkend BKMK_6}\pard \sb162 {\fs18 Securities registered pursuant to Section 12(b) of the Act:}\par \pard {\fs16 \u160?}\par {\trowd\trleft0\clbrdrb\brdrs\brdrw13\brdrcf0\clvertalb\cellx4360 \clbrdrb\brdrs\brdrw13\brdrcf0\clvertalb\cellx4494 \clbrdrb\brdrs\brdrw13\brdrcf0\clvertalb\cellx6227 \clbrdrb\brdrs\brdrw13\brdrcf0\clvertalb\cellx6361 \clbrdrb\brdrs\brdrw13\brdrcf0\clvertalb\cellx11520 \pard \intbl\qc \ri16 {\fs14\b Title of each class}\cell \pard \intbl\qc \ri16 {\fs14\b \u160?}\cell \pard \intbl\qc \ri16 {\fs14\b Trading}\par \pard \intbl\qc \ri16 {\fs14\b Symbol(s)}\cell \pard \intbl\qc \ri16 {\fs14\b \u160?}\cell \pard \intbl\qc \ri16 {\fs14\b Name of each exchange on which registered}\cell \row} {\trowd\trleft0\clbrdrt\brdrs\brdrw13\brdrcf0\cellx4360 \cellx4494 \clbrdrt\brdrs\brdrw13\brdrcf0\cellx6227 \cellx6361 \clbrdrt\brdrs\brdrw13\brdrcf0\cellx11520 \pard \intbl\qc \ri16 {\fs18 Common Stock (Par Value $0.001)}\cell \pard \intbl\qc \ri16 {\fs18 \u160?}\cell \pard \intbl\qc \ri16 {\fs18 ACOR}\cell \pard \intbl\qc \ri16 {\fs18 \u160?}\cell \pard \intbl\qc \ri16 {\fs18 Nasdaq Global Select Market}\cell \row} \pard \sb162 {\fs18 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (\u167?\u8201?230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (\u167?\u8201?240.12b-2 of this chapter).}\par \pard \sb162 {\fs18 Emerging growth company\u160?{\u9744?}}\par \pard \sb162 {\fs18 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.\u160?{\u9744?}}\par \pard \brdrb\brdrdb\brdrw40\brdrcf0 {\fs18 \u160?}\par \pard \sb90 {\fs8\b \u160?}\par \pard \qc \sb216 {\fs18 \u160?}\par \pard \li13\ri13\sb166 \brdrt\brdrs\brdrw13\brdrcf1\brdrr\brdrs\brdrw13\brdrcf1\brdrb\brdrs\brdrw13\brdrcf1\brdrl\brdrs\brdrw13\brdrcf1\sl-13\qc {\*\bkmkstart BKMK_7}{\*\bkmkend BKMK_7}\par \pard \pagebb {\fs18 \u160?}\par \pard {\fs18 \u160?}{\*\bkmkstart BKMK_8}{\*\bkmkend BKMK_8}{\*\bkmkstart BKMK_9}{\*\bkmkend BKMK_9}\par \pard {\fs20\b Item 2.01{Completion of Acquisition or Disposition of Assets}}\par \pard {\fs20 \u160?}\par \pard \fi768 {\fs20 On February 10, 2021, Acorda Therapeutics, Inc. (the \u8220?Company\u8221?) closed the transactions contemplated by its previously announced asset purchase agreement, dated January 12, 2021 (the \u8220?Asset Purchase Agreement\u8221?), pursuant to which the Company agreed to sell to Catalent Pharma Solutions, Inc. (\u8220?Catalent\u8221?) certain assets related to the Company\u8217?s manufacturing operations located at the facilities situated in Chelsea, Massachusetts and Waltham, Massachusetts, and Catalent agreed to assume certain liabilities relating to such manufacturing operations (the \u8220?Transaction\u8221?). At closing, Catalent paid the Company $80 million in cash, resulting in expected net proceeds of approximately $74 million after transaction fees and expenses and settlement of customary post-closing adjustments. The Company intends to use the net proceeds received from the Transaction for general corporate purposes, which may include funding capital expenditures and the repayment of indebtedness.}\par \pard {\fs20 \u160?}\par \pard \fi768 {\fs20 In connection with the closing of the Transaction, the Company and Catalent entered into certain additional ancillary agreements, including the Manufacturing Services Agreement described in the Company\u8217?s Current Report on Form 8-K that was filed on January 13, 2021, a transitional services agreement and certain other customary agreements.}\par \pard {\fs20 \u160?}\par \pard \fi768 {\fs20 The foregoing description of the Asset Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to such document, which will be filed as an exhibit to a future periodic or current report of the Company.}\par \pard {\fs20 \u160?}{\*\bkmkstart BKMK_10}{\*\bkmkend BKMK_10}{\*\bkmkstart BKMK_11}{\*\bkmkend BKMK_11}\par \pard {\fs20\b Item 8.01{Other Events}}\par \pard {\fs20 \u160?}\par \pard \fi768 {\fs20 On February 11, 2021, the Company issued a press release announcing the closing of the Transaction. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.}\par \pard {\fs20 \u160?}{\*\bkmkstart BKMK_12}{\*\bkmkend BKMK_12}{\*\bkmkstart BKMK_13}{\*\bkmkend BKMK_13}\par \pard {\fs20\b Item 9.01{Financial Statements and Exhibits}}\par \pard {\fs20 \u160?}\par \pard {\fs20 (b) Pro forma financial information.}\par \pard \fi768 {\fs20 \u160?}\par \pard \fi768 {\fs20 The following unaudited pro forma consolidated financial statements reflecting the transaction described under Item 2.01 above are filed with this Current Report on Form 8-K as Exhibit 99.2 and are incorporated herein by reference:}\par \pard \fi768 {\fs20 \u160?}\par {\trowd\trleft0\cellx784 \cellx1185 \cellx11520 \pard \intbl \ri16 {\fs18 \u160?}\cell \pard \intbl \ri16 {\fs20 {\u8226?}}\cell \pard \intbl \ri16 {\fs18 {\fs20 the Company\u8217?s unaudited pro forma consolidated balance sheet as of September 30, 2020;}}\cell \row} \pard \li1152 {\fs20 \u160?}\par {\trowd\trleft0\cellx784 \cellx1185 \cellx11520 \pard \intbl \ri16 {\fs18 \u160?}\cell \pard \intbl \ri16 {\fs20 {\u8226?}}\cell \pard \intbl \ri16 {\fs18 {\fs20 the Company\u8217?s unaudited pro forma consolidated statement of operations for the nine-month period ended September 30, 2020; and}}\cell \row} \pard \li768 {\fs20 \u160?}\par {\trowd\trleft0\cellx784 \cellx1185 \cellx11520 \pard \intbl \ri16 {\fs18 \u160?}\cell \pard \intbl \ri16 {\fs20 {\u8226?}}\cell \pard \intbl \ri16 {\fs18 {\fs20 the Company\u8217?s unaudited pro forma consolidated statement of operations for the fiscal year ended December 31, 2019.}}\cell \row} \pard {\fs20 \u160?}\par \pard \fi768 {\fs20 The unaudited pro forma consolidated financial statements are not intended to represent or be indicative of the Company\u8217?s consolidated results of operations or financial position that would have been reported had the disposition been completed as of the dates presented, and should not be taken as representation of the Company\u8217?s future consolidated results of operations or financial condition. The pro forma adjustments are based on available information and certain assumptions that management believes are reasonable under the circumstances.}\par \pard \fi383 {\fs20 \u160?}\par \pard {\fs20 (d) Exhibits}\par \pard {\fs20 \u160?}{\*\bkmkstart BKMK_14}{\*\bkmkend BKMK_14}\par {\trowd\trleft0\clvertalc\cellx1450 \clvertalc\cellx1747 \clvertalc\cellx10144 \pard \intbl\sl-1\vertalc \cell \pard \intbl\sl-1\vertalc \cell \pard \intbl\sl-1\vertalc \cell \row} {\trowd\trleft0\cellx1450 \cellx1747 \cellx10144 \pard \intbl \ri15 {\fs20\i {\ul Exhibit} {\ul No}{\i0\b .}}\cell \pard \intbl \ri16 {\fs20\b \u160?}\cell \pard \intbl \ri16 {\fs20\i {\ul Description}}\cell \row \pard \intbl \ri15 {\fs20 99.1}\cell \pard \intbl \ri16 {\fs20 \u160?}\cell \pard \intbl \ri16 {\fs20 {\field\fldedit{\*\fldinst { HYPERLINK "" \\l "BKMK_15"}}{\fldrslt\ul {{\ul Press release dated February 11, 2021.}}}}}\cell \row \pard \intbl \ri15 {\fs20 99.2}\cell \pard \intbl \ri16 {\fs20 \u160?}\cell \pard \intbl \ri16 {\fs20 {\field\fldedit{\*\fldinst { HYPERLINK "" \\l "BKMK_16"}}{\fldrslt\ul {{\ul Unaudited Pro Forma Financial Statements and accompanying notes.}}}}}\cell \row \pard \intbl \ri15 {\fs20 104}\cell \pard \intbl \ri16 {\fs20 \u160?}\cell \pard \intbl \ri16 {\fs20 Cover Page Interactive Data File (embedded within the Inline XBRL document).}\cell \row} \pard {\fs20 \u160?}\par \pard {\fs18 }\par \pard \qc \sb216 {\fs18 \u160?}\par \pard \li13\ri13\sb166 \brdrt\brdrs\brdrw13\brdrcf1\brdrr\brdrs\brdrw13\brdrcf1\brdrb\brdrs\brdrw13\brdrcf1\brdrl\brdrs\brdrw13\brdrcf1\sl-13\qc {\*\bkmkstart BKMK_17}{\*\bkmkend BKMK_17}\par \pard \pagebb {\fs18 \u160?}\par \pard \sb108 {\fs18 \u160?}{\*\bkmkstart BKMK_18}{\*\bkmkend BKMK_18}\par \pard \qc {\fs20\b SIGNATURES}\par \pard {\fs20 \u160?}\par \pard {\fs20 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.}\par \pard \qc {\fs20 \u160?}\par {\trowd\trleft0\cellx5857 \cellx11520 \pard \intbl \ri16 {\fs18 \u160?}\par \pard \intbl \ri16\sb180 {\fs20 \u160?}\cell \pard \intbl \ri36 {\fs20\b Acorda Therapeutics, Inc.}\cell \row} {\trowd\trleft0\cellx5857 \cellx6408 \cellx11520 \pard \intbl \ri16 {\fs20 \u160?}\cell \pard \intbl \ri16 {\fs20 \u160?}\cell \pard \intbl \ri16 {\fs20 \u160?}\cell \row} {\trowd\trleft0\clbrdrb\brdrs\brdrw18\brdrcf0\cellx5857 \clbrdrb\brdrs\brdrw18\brdrcf0\cellx6408 \clbrdrb\brdrs\brdrw18\brdrcf0\cellx11520 \pard \intbl \ri16 {\fs20 February 17, 2021}\cell \pard \intbl \ri16 {\fs20 By:}\cell \pard \intbl \ri16 {\fs20 /s/ David Lawrence}\cell \row} {\trowd\trleft0\cellx5857 \cellx6408 \cellx11520 \pard \intbl \ri16 {\fs20 \u160?}\cell \pard \intbl \ri16 {\fs20 \u160?}\cell \pard \intbl \ri16 {\fs20 Name: David Lawrence}\cell \row \pard \intbl \ri16 {\fs20 \u160?}\cell \pard \intbl \ri16 {\fs20 \u160?}\cell \pard \intbl \ri16 {\fs20 Title: Chief, Business Operations and Principal Accounting Officer}\cell \row} \pard \sb216 {\fs18 \u160?}\par \pard \qc \sb216 {\fs18 \u160?}\par \pard \sl-1 {\*\bkmkstart BKMK_19}{\*\bkmkend BKMK_19}{\*\bkmkstart BKMK_15}{\*\bkmkend BKMK_15}{\*\bkmkstart BKMK_20}{\*\bkmkend BKMK_20}\par \pard \qr \pagebb {\fs22\b EXHIBIT 99.1}\par \pard \qc {\fs22 {\pict\jpegblip\pichgoal931\picwgoal2916\bin15708 JFIF ` ` C $.' ",#(7),01444'9=82<.342 C 2!!22222222222222222222222222222222222222222222222222 " } !1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w !1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ? ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( LsKH܌g Cx=)=+XM!5{Ofk`QFh((((((((((((((((((((((( (8kkm$ȯ8acrΈR4hen?AVzm2< ze hI;M@Q@Q@R Z(אF߅hW;Fӷ,AXutkv+=@RQ9[$d<ɣeNàK[W]e#R \ oQLY2C$1N Z*\G /> )oɦhJ+ռq}+͢Ch Z++r4-VLp(vv<rk~(:\'b)xRɴ9dpz}2_xd'WĂ8a\?mKM"+L'ֻ;Q@Q@ī!'5 ѱnXvVjѻ]')?u X^ ?I ?tt +OƝ%>Sr mBv{P} zu@O "'̄&=ivg }̷LqMvX.OA@^uJnLsH3tcɺOPQ^L}]')l~B=^o]Z88I w.~B=^;_z(t_?}YEU1%SVF{ Z( QE QE QGAKga<: +>P0)thxL zxw. Z2pHv